ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.08) by 725 percent. This is a 725 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $6.15 million which missed the analyst consensus estimate of $6.58 million by 6.59 percent. This is a 1.13 percent decrease over sales of $6.22 million the same period last year.